60
Lisata Therapeutics closes $351.9M raise in business combination
Company raise · Closed · BASKING RIDGE, NJ · Form D filed 2026-10-02
Lisata Therapeutics, a Delaware biotech corporation based in Basking Ridge, NJ, has closed a $351.9M offering under Regulation D exemption 6(b). The raise involved 20 investors and was facilitated by three placement agents: H.C. Wainwright & Co., Leerink Partners, and LifeSci Capital.
Note: Raise involved non-accredited investors under Regulation D 6(b); business combination structure noted in flags.
$50M+ raisePlacement agent engagedBusiness combinationNon-accredited investorsother
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
People on the filing
| DAVID MAZZO | Executive Officer, Director |
| JAMES NISCO | Executive Officer |
| TARIQ IMAM | Executive Officer |
| GREGORY BROWN | Director |
| HEIDI HENSON | Director |
| CYNTHIA FLOWERS | Director |
| STEVEN KLOSK | Director |
| MOHAMMAD AZAB | Director |
| TED LOVE | Director |
Signed by David Mazzo, CEO.
Placement agents / sales compensation: H.C.WAINWRIGHT & CO., LLC; LEERINK PARTNERS LLC; LIFESCI CAPITAL
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.